IDT Australia Ltd - Asset Resilience Ratio
IDT Australia Ltd (IDT) has an Asset Resilience Ratio of 9.76% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See IDT working capital efficiency to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2016–2025)
This chart shows how IDT Australia Ltd's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see IDT asset base.
Liquid Assets Composition Over Time
This chart breaks down IDT Australia Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read total liabilities of IDT Australia Ltd for a breakdown of total debt and financial obligations.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | AU$0.00 | 0% |
| Short-term Investments | AU$3.60 Million | 9.76% |
| Total Liquid Assets | AU$3.60 Million | 9.76% |
Asset Resilience Insights
- Limited Liquidity: IDT Australia Ltd maintains only 9.76% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
IDT Australia Ltd Industry Peers by Asset Resilience Ratio
Compare IDT Australia Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
ST:SOBI |
Drug Manufacturers - Specialty & Generic | 1.54% |
|
Yunnan Baiyao Group Co Ltd
SHE:000538 |
Drug Manufacturers - Specialty & Generic | 8.38% |
|
Guangdong Zhongsheng Pharmaceutical Co Ltd
SHE:002317 |
Drug Manufacturers - Specialty & Generic | 6.62% |
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK |
Drug Manufacturers - Specialty & Generic | 4.94% |
|
Harbin Gloria Pharmaceuticals
SHE:002437 |
Drug Manufacturers - Specialty & Generic | 9.04% |
|
Jiuzhitang Co Ltd
SHE:000989 |
Drug Manufacturers - Specialty & Generic | 7.86% |
|
Renhe Pharmacy Co Ltd
SHE:000650 |
Drug Manufacturers - Specialty & Generic | 37.54% |
|
Jiangsu Kanion Pharmaceutical Co Ltd
SHG:600557 |
Drug Manufacturers - Specialty & Generic | 0.29% |
Annual Asset Resilience Ratio for IDT Australia Ltd (2016–2025)
The table below shows the annual Asset Resilience Ratio data for IDT Australia Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-06-30 | 9.76% | AU$3.60 Million ≈ $2.55 Million |
AU$36.92 Million ≈ $26.12 Million |
+8.48pp |
| 2024-06-30 | 1.28% | AU$400.00K ≈ $283.03K |
AU$31.37 Million ≈ $22.20 Million |
-- |
| 2017-06-30 | 0.00% | AU$0.00 ≈ $0.00 |
AU$58.12 Million ≈ $41.12 Million |
-- |
| 2016-06-30 | 0.00% | AU$0.00 ≈ $0.00 |
AU$52.91 Million ≈ $37.44 Million |
-- |
About IDT Australia Ltd
IDT Australia Limited engages in the research, development, manufacture, and sale of active pharmaceutical ingredients (API) and finished dose forms (FDF) products in Australia, Asia, Europe, and the United States. The company offers microbiological and analytical testing, clinical packaging, and pharmacy services. It also provides medicinal cannabis and psychedelics; oral finished doses; and ase… Read more